Breaking News, Collaborations & Alliances

RoosterBio, Senti Biosciences Partner on Cell Therapy

Collaboration leverages cGMP clinical systems to accelerate gene modified cell therapy for solid tumors

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

RoosterBio has entered a clinical supply and manufacturing collaboration agreement with gene circuit company Senti Biosciences to accelerate the clinical translation of Senti’s gene-modified cell therapies for ovarian cancer and other solid tumor indications. The collaboration will leverage RoosterBio’s human mesenchymal stem/stromal cell (hMSC) bioprocess systems, rapid product and process development platform, and current Good Manufacturing Practices (cGMP)-compliant, hMSC-focused manufacturin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters